Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online calls, meetings, and deadlines has predictably returned. But you knew this was coming, yes? So time to fortify ourselves with a delicious cup of stimulation. Our choice today is the great pumpkin, so to speak. Feel free to join us. Meanwhile, we have taken advantage of some quiet time — courtesy of the snoozing official mascot — to assemble a few items of interest. Hope your day goes well and, as always, do keep in touch. We enjoy your postcards. …

Regeneron Pharmaceuticals (REGN) reported a single dose of its antibody cocktail reduced the risk of contracting Covid-19 by 81.6% in the two to eight months following administration in a late-stage trial, Reuters writes. The results showed the antibody therapy, REGEN-COV, may provide long-lasting immunity from Covid-19 infection, according to Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network. Such immunity is important for immunocompromised people and those not responding to vaccines. The therapy had previously shown an 81.4% reduction risk during the first month after administration.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment